In short
Clinical trials are investigating LIQUID EXTRACT OF THYME (1:3.45-3.85), EXTRACTION SOLVENT: ETHANOL 27%(V/V) in children with acute bronchitis. These studies aim to assess clinical efficacy and safety, and to see whether it may help reduce unnecessary antibiotic use.
Key points
- Clinical trials are investigating LIQUID EXTRACT OF THYME (1:3.45-3.85), EXTRACTION SOLVENT: ETHANOL 27%(V/V) for acute bronchitis in children. The study is a randomized, double-blind, placebo-controlled trial, which means treatment groups are assigned by chance and neither the families nor the study team know who gets which treatment. It is listed as Phase 3 and includes 56 participants. The main goal is to measure efficacy and safety, with symptom severity checked using the Bronchitis Severity Score. The trial also aims to better understand whether this treatment may help reduce inappropriate antibiotic use in children with acute bronchitis.
Trial overview
The clinical trial with NCT ID 2025-520845-61-00 is studying LIQUID EXTRACT OF THYME (1:3.45-3.85), EXTRACTION SOLVENT: ETHANOL 27%(V/V) in children with acute bronchitis. The study is designed to assess whether the treatment can help in this condition and whether it is safe to use in the target group.
Study design and phase
This is an interventional study, which means the researchers give a treatment and then measure the results. It is described as double-blind, randomized, and placebo-controlled. These terms mean that treatment groups are assigned by chance, and neither the participants nor the researchers know who receives the study treatment or the placebo during the trial. The trial is listed as Phase 3 and has an enrollment of 56 participants.
Who can participate
The target population is pediatric patients, meaning children. The trial data do not provide more detailed age limits or other eligibility rules. The study focuses on children who have acute bronchitis.
What is being measured
The main endpoint is the efficacy of the investigational product based on the Bronchitis Severity Score. Efficacy means how well the treatment works in the study. The Bronchitis Severity Score is used to measure how severe the bronchitis symptoms are.
The brief summary also says the study is looking at safety and at whether the treatment may help reduce inappropriate antibiotic use in acute bronchitis in children. This shows that the trial is not only about symptom relief, but also about better treatment use in practice.
Why this study matters
Acute bronchitis in children can lead to treatment decisions that are not always ideal, including antibiotic use when it may not be needed. This trial is trying to learn whether LIQUID EXTRACT OF THYME (1:3.45-3.85), EXTRACTION SOLVENT: ETHANOL 27%(V/V) can be a useful option for this condition in a controlled research setting. Because the study is placebo-controlled, it can help compare the study treatment with a look-alike treatment that has no active drug.
Trial details at a glance
| Item | Information |
|---|---|
| Trial ID | 2025-520845-61-00 |
| Status | Authorised |
| Condition | Acute bronchitis |
| Population | Pediatric patients |
| Design | Double-blind, randomized, placebo-controlled |
| Phase | Phase 3 |
| Enrollment | 56 |
| Main endpoint | Efficacy based on the Bronchitis Severity Score |